Oncobiologics (NASDAQ:OTLK – Get Free Report) and enGene (NASDAQ:ENGN – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, risk, valuation and institutional ownership.
Profitability
This table compares Oncobiologics and enGene’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Oncobiologics | N/A | N/A | -276.35% |
| enGene | N/A | -56.06% | -45.64% |
Insider and Institutional Ownership
11.2% of Oncobiologics shares are held by institutional investors. Comparatively, 64.2% of enGene shares are held by institutional investors. 1.8% of Oncobiologics shares are held by insiders. Comparatively, 10.5% of enGene shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Risk and Volatility
Analyst Recommendations
This is a breakdown of recent recommendations for Oncobiologics and enGene, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Oncobiologics | 1 | 4 | 2 | 0 | 2.14 |
| enGene | 2 | 8 | 4 | 0 | 2.14 |
Oncobiologics presently has a consensus price target of $4.65, suggesting a potential upside of 582.82%. enGene has a consensus price target of $11.05, suggesting a potential upside of 525.80%. Given Oncobiologics’ higher possible upside, research analysts plainly believe Oncobiologics is more favorable than enGene.
Valuation & Earnings
This table compares Oncobiologics and enGene”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Oncobiologics | $1.35 million | 74.96 | -$62.42 million | ($0.77) | -0.88 |
| enGene | N/A | N/A | -$117.30 million | ($2.17) | -0.81 |
Oncobiologics has higher revenue and earnings than enGene. Oncobiologics is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.
Summary
Oncobiologics beats enGene on 6 of the 11 factors compared between the two stocks.
About Oncobiologics
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
About enGene
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.
Receive News & Ratings for Oncobiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics and related companies with MarketBeat.com's FREE daily email newsletter.
